Effectiveness decreasing hypertension when aspirin drug's administration schedule is at night.

Phase 1

• Conditions: hypertension; MedDRA version: 14.1Level: LLTClassification code 10020775Term: Hypertension arterialSystem Organ Class: 10047065 - Vascular disorders; Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

• Registration Number: EUCTR2011-004760-29-ES
• Lead Sponsor: Maria Victoria Ruiz Arzalluz

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-11-22
• Last Update Posted: 23 October 2017

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 258

Inclusion Criteria

All participants are to be hypertensive patients (?140/90) between 18 and 80 years old who are currently taking low doses of ASA, for secondary prevention of cardiovascular events
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 230
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 28

Exclusion Criteria

Severe and/or terminal illness
Congestive heart failure (CHF)
Moderate/severe chronic renal failure
Physical or mental illness that prevents the patient´s collaboration
Being a heavy drinker, consuming more than 280 g of alcohol per week in the case of men or 170 g for women31
Concomitant treatment with other antiplatelets or anticoagulants
Taking NSAIDs on a regular basis
Treatment with ASA at doses outside those established in the inclusion criteria (above)
ASA already being taken in the evening
Being a shift worker or having a very intensive work schedule
Hospital admission during the clinical trial

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified